HDM201 Added to CT in R/R or Newly Diagnosed AML

Stopped It was determined that the study design may not be optimal given the changing AML treatment landscape.

Conditions

• Leukemia, Myeloid, Acute

Interventions

• DRUG: HDM201
• DRUG: cytarabine
• DRUG: anthracycline
• DRUG: midostaurin
• DRUG: liposomal cytarabine/daunorubicin
• DRUG: posaconazole
• DRUG: midazolam

Sponsor

Novartis Pharmaceuticals